Wells Fargo Securities Healthcare Conference (Immunomedics) - Jun 20, 2012 - Anticipated initiation of pts enrollment for P2 VELVET trial for rheumatoid arthritis in H2 2012
Anticipated enrollment status • Rheumatoid Arthritis
|
|
Veltuzumab
---
Anticipated initiation of patient enrollment for P2 VELVET trial for rheumatoid arthritis in H2 2012
----
|